Lantern Pharma Reports Positive Phase 1a Results for LP-184 and Advances AI-Driven Oncology Pipeline

Lantern Pharma reported third-quarter 2025 results demonstrating substantial progress across its AI-driven oncology pipeline, highlighted by the completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial. The trial results showed a 48% clinical benefit rate at or above the therapeutic dose threshold, along with a favorable safety profile and strong biomarker correlations. These positive outcomes validate the company's AI-powered approach to drug development and provide strong foundation for advancing the program into later-stage clinical studies.

The company outlined specific plans for Phase 1b/2 studies targeting triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) with STK11/KEAP1 co-mutations, and bladder cancer. Pharmacokinetic data from the Phase 1a trial established a recommended Phase 2 dose of 0.39 mg/kg, providing clear guidance for future clinical development. This dose optimization represents a critical milestone in the drug's development pathway and supports the planned expansion into multiple cancer indications where significant unmet medical needs exist.

Beyond the LP-184 program, Lantern Pharma noted catalyst-rich progress across its broader pipeline. The company gained regulatory clarity for its pediatric central nervous system cancer program following a productive FDA Type C meeting, potentially accelerating development timelines for this challenging patient population. Additionally, increased commercial interest emerged for LP-284, another promising asset in the company's portfolio. These developments collectively demonstrate the scalability and efficiency of Lantern's AI-driven drug discovery platform in advancing multiple therapeutic candidates simultaneously.

The company's proprietary AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms. This technological infrastructure enables Lantern Pharma to address complex challenges in oncology drug development while potentially reducing costs and timelines. The platform's ability to identify promising drug candidates and optimize their development pathways represents a significant advancement in how cancer therapies are discovered and developed, potentially transforming the traditional pharmaceutical research model.

Lantern Pharma's growing pipeline of therapies spans multiple cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company's lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials, reflecting a balanced portfolio across different development stages. The full details of the company's quarterly performance and pipeline updates are available in their official release at https://ibn.fm/7zA4s. Additional information about the company's ongoing developments can be found through their corporate communications at https://ibn.fm/LTRN.